NO20045373L - Cyanoguanidinprodroger - Google Patents

Cyanoguanidinprodroger

Info

Publication number
NO20045373L
NO20045373L NO20045373A NO20045373A NO20045373L NO 20045373 L NO20045373 L NO 20045373L NO 20045373 A NO20045373 A NO 20045373A NO 20045373 A NO20045373 A NO 20045373A NO 20045373 L NO20045373 L NO 20045373L
Authority
NO
Norway
Prior art keywords
cyanoguanidinprodroger
prodrugs
cancers
pyridyl
human
Prior art date
Application number
NO20045373A
Other languages
English (en)
Inventor
Ernst Torndal Blinderup
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of NO20045373L publication Critical patent/NO20045373L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pyridyl-cyanoguanidinforbindelser ifølge formel I R, R4 R5 R, ['] hvori A, Ri, R2, R5, Re/ Xi, X2, X3, X4, Yi, Y2, Y3, Y4 og n er som indikert i beskrivelsen er nyttige som prodroger i human og veterinær terapi av proliferative sykdommer slik som cancere.
NO20045373A 2002-05-17 2004-12-08 Cyanoguanidinprodroger NO20045373L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38085602P 2002-05-17 2002-05-17
PCT/DK2003/000319 WO2003097602A1 (en) 2002-05-17 2003-05-15 Cyanoguanidine produgs

Publications (1)

Publication Number Publication Date
NO20045373L true NO20045373L (no) 2004-12-08

Family

ID=29550027

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045373A NO20045373L (no) 2002-05-17 2004-12-08 Cyanoguanidinprodroger

Country Status (15)

Country Link
US (1) US20060014804A1 (no)
EP (1) EP1507759A1 (no)
JP (1) JP2005531560A (no)
KR (1) KR20040111626A (no)
CN (1) CN1662502A (no)
AU (1) AU2003223932A1 (no)
BR (1) BR0309988A (no)
CA (1) CA2484671A1 (no)
IL (1) IL164986A0 (no)
IS (1) IS7563A (no)
MX (1) MXPA04011324A (no)
NO (1) NO20045373L (no)
PL (1) PL372761A1 (no)
RU (1) RU2004136989A (no)
WO (1) WO2003097602A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE368649T1 (de) * 2002-05-17 2007-08-15 Leo Pharma As Cyanoguanidin prodrugs
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
US7262334B2 (en) * 2002-11-13 2007-08-28 Regents Of The University Of Minnesota Catalytic partial oxidation of hydrocarbons
JP5189367B2 (ja) * 2004-12-22 2013-04-24 レオ ファーマ アクティーゼルスカブ 新規シアノグアニジン化合物
US8173677B2 (en) 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
EP2197443A4 (en) 2007-09-26 2014-01-01 Gemin X Pharmaceuticals Canada Inc COMPOSITIONS AND METHODS FOR INFLUENCING NAD + CONTENT USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE INHIBITOR
WO2009089053A1 (en) * 2008-01-11 2009-07-16 Nektar Therapeutics Al, Corporation Oligomer-guanidine class conjugates
RU2011111728A (ru) 2008-08-29 2012-10-10 Топотаргет А/С (Dk) Новые производные мочевины и тиомочевины
CA2751495C (en) 2009-02-06 2013-08-20 Tianjin Hemay Bio-Tech Co., Ltd. Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof
US20120270900A1 (en) 2009-07-17 2012-10-25 Topo Target A/S Novel method of treatment
IL291810A (en) 2016-10-18 2022-06-01 Seagen Inc Targeted administration of nicotinamide adenine dinucleotide reductase pathway inhibitors
BR112019022445A2 (pt) * 2017-04-27 2020-05-12 Seattle Genetics, Inc. Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9711125D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
WO2000061559A1 (en) * 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. N-substituted cyanoguanidine compounds
AU1494702A (en) * 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases

Also Published As

Publication number Publication date
KR20040111626A (ko) 2004-12-31
WO2003097602A1 (en) 2003-11-27
IS7563A (is) 2004-11-29
MXPA04011324A (es) 2005-02-17
US20060014804A1 (en) 2006-01-19
JP2005531560A (ja) 2005-10-20
RU2004136989A (ru) 2005-06-27
CA2484671A1 (en) 2003-11-27
IL164986A0 (en) 2005-12-18
CN1662502A (zh) 2005-08-31
BR0309988A (pt) 2005-02-22
EP1507759A1 (en) 2005-02-23
PL372761A1 (en) 2005-08-08
AU2003223932A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
ATE302775T1 (de) Carbolinderivate
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
EG25017A (en) N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials.
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
ATE346067T1 (de) Carbolinderivate
HK1076812A1 (en) Cyanoguanidine prodrugs
NO20062629L (no) Oksazolderivater av tetrackliner
NO331012B1 (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
NO20070570L (no) Forbindelser.
NO20045373L (no) Cyanoguanidinprodroger
SE0101932D0 (sv) Pharmaceutical combinations
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
BG108498A (en) New derivatives of oxazolidinones as antibacterial agents
NO20044526L (no) Hemisterlinderivater og anvendelser derav
NO20024662D0 (no) Prodroger av imidazopyridinderivater
GB0229081D0 (en) Multifunctional cationic photoinitiators, their preparation and use
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
NO20053562L (no) Nye aminobenzofenonforbindelser
SE0004827D0 (sv) Therapeutic compounds
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents
GEP20084343B (en) Use of indole derivatives for the treatment of neuropathic pain
DE69903024D1 (de) Thiocolchicosid-derivate, ihre herstellung und verwendung als arzneimittel